PDF(Pubmed)
Abstract：
UNASSIGNED: Dry eye disease (DED) is a multifactorial ocular surface disease with a rising incidence. Therefore, it is urgent to construct a reliable and efficient drug delivery system for DED treatment.
UNASSIGNED: In this work, we loaded C-dots nanozyme into a thermosensitive in situ gel to create C-dots@Gel, presenting a promising composite ocular drug delivery system to manage DED.
UNASSIGNED: This composite ocular drug delivery system (C-dots@Gel) demonstrated the ability to enhance adherence to the corneal surface and extend the ocular surface retention time, thereby enhancing bioavailability. Furthermore, no discernible ocular surface irritation or systemic toxicity was observed. In the DED mouse model induced by benzalkonium chloride (BAC), it was verified that C-dots@Gel effectively mitigated DED by stabilizing the tear film, prolonging tear secretion, repairing corneal surface damage, and augmenting the population of conjunctival goblet cells.
UNASSIGNED: Compared to conventional dosage forms (C-dots), the C-dots@Gel could prolong exhibited enhanced retention time on the ocular surface and increased bioavailability, resulting in a satisfactory therapeutic outcome for DED.
UNASSIGNED: In this work, we loaded C-dots nanozyme into a thermosensitive in situ gel to create C-dots@Gel, presenting a promising composite ocular drug delivery system to manage DED.
UNASSIGNED: This composite ocular drug delivery system (C-dots@Gel) demonstrated the ability to enhance adherence to the corneal surface and extend the ocular surface retention time, thereby enhancing bioavailability. Furthermore, no discernible ocular surface irritation or systemic toxicity was observed. In the DED mouse model induced by benzalkonium chloride (BAC), it was verified that C-dots@Gel effectively mitigated DED by stabilizing the tear film, prolonging tear secretion, repairing corneal surface damage, and augmenting the population of conjunctival goblet cells.
UNASSIGNED: Compared to conventional dosage forms (C-dots), the C-dots@Gel could prolong exhibited enhanced retention time on the ocular surface and increased bioavailability, resulting in a satisfactory therapeutic outcome for DED.
摘要：
■干眼病（DED）是一种多因素眼表疾病，发病率不断上升。因此,构建可靠、高效的DED给药系统已成为当务之急。
■在这项工作中，我们将C点纳米酶加载到热敏原位凝胶中以创建C点@凝胶，提出了一种有前途的复合眼部药物递送系统来管理DED。
■这种复合眼部药物递送系统（C-dots@Gel）证明了增强对角膜表面的粘附力并延长眼表保留时间的能力，从而提高生物利用度。此外，未观察到明显的眼表刺激或全身毒性.在苯扎氯铵（BAC）诱导的DED小鼠模型中，验证了C-dots@Gel通过稳定泪膜有效缓解DED，延长泪液分泌，修复角膜表面损伤，增加结膜杯状细胞的数量。
■与常规剂型（C点）相比，C-dots@Gel可以延长在眼表的保留时间，增加生物利用度，对DED的治疗效果令人满意。
■在这项工作中，我们将C点纳米酶加载到热敏原位凝胶中以创建C点@凝胶，提出了一种有前途的复合眼部药物递送系统来管理DED。
■这种复合眼部药物递送系统（C-dots@Gel）证明了增强对角膜表面的粘附力并延长眼表保留时间的能力，从而提高生物利用度。此外，未观察到明显的眼表刺激或全身毒性.在苯扎氯铵（BAC）诱导的DED小鼠模型中，验证了C-dots@Gel通过稳定泪膜有效缓解DED，延长泪液分泌，修复角膜表面损伤，增加结膜杯状细胞的数量。
■与常规剂型（C点）相比，C-dots@Gel可以延长在眼表的保留时间，增加生物利用度，对DED的治疗效果令人满意。
